Transcriptional Alterations by Ischaemic Postconditioning in a Pig Infarction Model: Impact on Microvascular Protection.
Animals
Cell Size
Cluster Analysis
Disease Models, Animal
Focal Adhesions
/ metabolism
High-Throughput Nucleotide Sequencing
Ischemic Postconditioning
Microvessels
/ pathology
Myocardial Infarction
/ genetics
Myocardial Reperfusion Injury
/ genetics
RNA, Messenger
/ genetics
Reproducibility of Results
Survival Analysis
Swine
Transcription, Genetic
acute myocardial infarction
ischemia-reperfusion injury
ischemic postconditioning
porcine model
transcriptome
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Jan 2019
15 Jan 2019
Historique:
received:
30
11
2018
revised:
04
01
2019
accepted:
08
01
2019
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
30
4
2019
Statut:
epublish
Résumé
Although the application of cardioprotective ischaemia/reperfusion (I/R) stimuli after myocardial infarction (MI) is a promising concept for salvaging the myocardium, translation to a clinical scenario has not fulfilled expectations. We have previously shown that in pigs, ischaemic postconditioning (IPostC) reduces myocardial oedema and microvascular obstruction (MVO), without influencing myocardial infarct size. In the present study, we analyzed the mechanisms underlying the IPostC-induced microvascular protection by transcriptomic analysis, followed by pathway analysis. Closed-chest reperfused MI was induced by 90 min percutaneous balloon occlusion of the left anterior descending coronary artery, followed by balloon deflation in anaesthetised pigs. Animals were randomised to IPostC (
Identifiants
pubmed: 30650650
pii: ijms20020344
doi: 10.3390/ijms20020344
pmc: PMC6358966
pii:
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Austrian Science Fund
ID : I 1277
Organisme : Országos Tudományos Kutatási Alapprogramok
ID : ANN107803
Organisme : Országos Tudományos Kutatási Alapprogramok
ID : K 105555/KPI01277FW
Organisme : European Cooperation in Science and Technology
ID : CA16225
Organisme : Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal
ID : NVKP_16-1-2016-0017
Organisme : Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal
ID : OTKA KH 125570
Organisme : Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal
ID : OTKA 115378
Déclaration de conflit d'intérêts
P.F. is the founder and CEO of Pharmahungary, a group of R&D companies. The other authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Circulation. 2000 Apr 18;101(15):1833-9
pubmed: 10769285
Cardiovasc Res. 2004 Apr 1;62(1):74-85
pubmed: 15023554
J Am Coll Cardiol. 2004 Sep 1;44(5):1103-10
pubmed: 15337225
Cardiovasc Res. 2004 Oct 1;64(1):61-71
pubmed: 15364614
Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68
pubmed: 15688067
Circulation. 2005 Sep 27;112(13):1971-8
pubmed: 16172266
Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1011-8
pubmed: 16214840
Cardiovasc Res. 2006 Jan;69(1):178-85
pubmed: 16216231
Circulation. 2006 Feb 21;113(7):1015-9
pubmed: 16476844
Basic Res Cardiol. 2006 Nov;101(6):502-7
pubmed: 16830072
J Interv Cardiol. 2006 Oct;19(5):367-75
pubmed: 17020559
J Am Coll Cardiol. 2009 May 12;53(19):1814-22
pubmed: 19422991
Am J Physiol Heart Circ Physiol. 2010 Jan;298(1):H152-7
pubmed: 19880666
Thromb Haemost. 2010 Aug;104(2):376-84
pubmed: 20352158
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
JACC Cardiovasc Interv. 2010 Jul;3(7):695-704
pubmed: 20650430
Eur Heart J. 2012 Jan;33(1):103-12
pubmed: 21846677
Molecules. 2012 Mar 27;17(4):3805-17
pubmed: 22453931
J Am Coll Cardiol. 2012 Jun 12;59(24):2175-81
pubmed: 22676937
Nat Protoc. 2012 Jul 12;7(8):1479-96
pubmed: 22790084
J Cardiovasc Magn Reson. 2012 Sep 29;14:68
pubmed: 23021401
Catheter Cardiovasc Interv. 2013 Nov 1;82(5):E662-71
pubmed: 23804529
J Am Heart Assoc. 2013 Sep 30;2(5):e000457
pubmed: 24080910
Chem Biol Interact. 2014 Jul 25;218:89-98
pubmed: 24835546
Basic Res Cardiol. 2015 Jan;110(1):452
pubmed: 25449894
Curr Drug Targets. 2015;16(8):904-11
pubmed: 25915487
Am Heart J. 2015 May;169(5):639-46
pubmed: 25965711
Am J Transl Res. 2015 Dec 15;7(12):2603-11
pubmed: 26885260
JAMA Cardiol. 2017 May 1;2(5):490-497
pubmed: 28249094
Sci Rep. 2017 Mar 07;7:43958
pubmed: 28266659
J Transl Med. 2017 Apr 1;15(1):67
pubmed: 28364777
Cardiovasc Res. 2017 May 1;113(6):564-585
pubmed: 28453734
Cardiovasc Res. 2017 Jun 1;113(7):725-736
pubmed: 28460026
Sci Rep. 2017 Sep 27;7(1):12343
pubmed: 28955040
Eur Radiol. 2018 Dec 14;:null
pubmed: 30552479
Am Heart J. 1996 Jul;132(1 Pt 1):78-83
pubmed: 8701879